Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Pharming Group N.V.NASDAQ: PHAR

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow turns negative

Q1 FY2026 investing cash flow was -$85.07M, compared with $9.69M a year earlier. Trailing-twelve-month investing cash flow was -$70.52M. Over 3 fiscal years it compounded at +51.3% a year.

Context

  • Investing cash flow amounted to 4.9% of revenue in FY2025, down 5.8 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near -$85.07M or moves back toward the trailing-twelve-month quarterly average of -$17.63M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$85.07M+133212.6% QoQ
Last fiscal yearDec 2025
$18.43M-43.7% YoY
LTMMar 2026
-$70.52M-273.6% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-977.8%——
1 year-43.7%——
3-year CAGR+51.3%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
18.43M USD
Year-over-year change
-43.7%

Investing Cash Flow vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -273.6% is the 8th highest of 9, against a peer median of +4.1%.
  • Investing cash flow amounts to 19.1% of revenue for PHAR, versus a peer median of 302.6%.
PHAR Competitors
Investing Cash Flow for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$4.68T USD+1585365.8%+174.5%455.9%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$448.71M USD-643.8%-52.6%47.7%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$240.69M USD+14.6%+1.9%25.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$200.01M USD-6.5%-7.8%302.6%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$179.25M USD+363.9%——
STOKStoke Therapeutics, Inc.LTM Mar 2026$149.75M USD+44.2%+59.7%466.8%
PHARPharming Group N.V.LTM Mar 2026$70.52M USD-273.6%+51.3%19.1%
SLNSilence Therapeutics plcLTM Mar 2026$6.39M USD—+32.8%693.3%
PRQRProQR Therapeutics N.V.LTM Mar 2026€955.79K EUR-107.1%+11.8%7.1%
PHVSPharvaris N.V.LTM Sep 2026€81.4K EUR-74.9%+9.8%—
Peer median (excluding PHAR) —+4.1%+10.8%302.6%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.